Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 13/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5754941 | 0.81 | GNRHR (0.65) | GNRHRADORA2AADORA1 | |
| SCHEMBL5754581 | 0.81 | GNRHR (0.64) | GNRHRADORA2AADORA1 | |
| SCHEMBL5755646 | 0.80 | GNRHR (0.59) | GNRHR | |
| SCHEMBL5755656 | 0.79 | NTRK1 (0.58) | NTRK1IGF1RFGFR1NTRK2 | |
| SCHEMBL6615473 | 0.79 | GNRHR (0.59) | GNRHRADORA2AADORA1 | |
| SCHEMBL5757060 | 0.74 | GNRHR (1.00) | GNRHR | |
| SCHEMBL5756644 | 0.74 | GNRHR (1.00) | GNRHR | |
| SCHEMBL5756641 | 0.74 | GNRHR (1.00) | GNRHR | |
| SCHEMBL13966235 | 0.73 | ADORA2A (0.76) | GNRHRADORA2AADORA1 | |
| SCHEMBL4516918 | 0.72 | ADORA2A (1.00) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412338-B1 | 1,3,5-TRIAZINE-2,4,6-TRIONES, PREPARATION AND USE AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040162290-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-08-19 | — | — | US | disclosed |
| US-6677340-B2 | ADMINISTERING HEXAHYDRO-1,3-5-TRIAZINE-2,4,6-TRIONE DERIVATIVE AS ANTICARCINOGENIC AGENT; BENIGN PROSTATIC HYPERPLASIA, SLEEP DISORDER TREATMENT | NEUROCRINE BIOSCIENCES, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030130282-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130282-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GNRHR 1/4885ADORA2A 386/4885ADORA1 332/4885 |
| US-20040162290-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GNRHR 1/4885ADORA2A 386/4885ADORA1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.